Acasti Pharma EBITDA 2014-2024 | GRCE
Acasti Pharma ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Acasti Pharma Annual EBITDA
(Millions of US $) |
| 2024 |
$-13 |
| 2023 |
$-52 |
| 2022 |
$-16 |
| 2021 |
$-15 |
| 2020 |
$-22 |
| 2019 |
$-32 |
| 2018 |
$-13 |
| 2017 |
$-6 |
| 2016 |
$-6 |
| 2015 |
$-5 |
| 2015 |
$ |
| 2014 |
$-9 |
| 2014 |
$ |
| 2013 |
$-6 |
| 2013 |
$ |
Acasti Pharma Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$-5 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-3 |
| 2023-09-30 |
$-2 |
| 2023-06-30 |
$-4 |
| 2023-03-31 |
$-38 |
| 2022-12-31 |
$-4 |
| 2022-09-30 |
$-5 |
| 2022-06-30 |
$-5 |
| 2022-03-31 |
$-4 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-4 |
| 2021-06-30 |
$-3 |
| 2021-03-31 |
$-2 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-8 |
| 2020-06-30 |
$-4 |
| 2020-03-31 |
$-3 |
| 2019-12-31 |
$-6 |
| 2019-09-30 |
$-6 |
| 2019-06-30 |
$-7 |
| 2019-03-31 |
$-10 |
| 2018-12-31 |
$-8 |
| 2018-09-30 |
$-7 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$-5 |
| 2017-12-31 |
$-3 |
| 2017-09-30 |
$-3 |
| 2017-06-30 |
$-2 |
| 2017-02-28 |
$-1 |
| 2016-11-30 |
$-1 |
| 2016-08-31 |
$-1 |
| 2016-05-31 |
$-2 |
| 2016-03-31 |
$0 |
| 2016-02-29 |
|
| 2015-12-31 |
$1 |
| 2015-09-30 |
$-2 |
| 2015-06-30 |
$-2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$-2 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$-3 |
| 2014-03-31 |
$1 |
| 2014-02-28 |
|
| 2013-12-31 |
$-3 |
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-2 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
